Covid-19 Infection In Solid Organ Transplant Recipients After Sars-Cov-2 Vaccination

The prevalence and mortality of COVID-19 are higher in solid organ transplant recipients (SOTs) compared to the general population (1-3). Two SARS-CoV-2 messenger RNA (mRNA) vaccines have been approved by the FDA, both are 95% efficient in preventing COVID-19 in the general population. The efficacy of these vaccines in SOTs remains to be unknown as immunocompromised patients have been excluded from the vaccine studies.